Dr. Tahir Yusufaly's current research applies quantitative modeling in order to predict therapeutic responses to radionuclide therapy, specifically alpharadiopharmaceutical therapy (alpha-RPT).
Dr. Yusufaly earned his Ph.D. in physics from Rutgers University. He then worked in postdoctoral research in biochemistry and molecular biology at Michigan State University, theoretical biophysics at the University of Southern California, and medical physics at the University of California San Diego. He received his M.S. in Medical Physics from Georgia Tech University.